-
Je něco špatně v tomto záznamu ?
Where are we with pre-exposure prophylaxis use in Central and Eastern Europe? Data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group
T. Balayan, J. Begovac, A. Skrzat-Klapaczyńska, I. Aho, I. Alexiev, P. Bukovinova, D. Salemovic, D. Gokengin, A. Harxhi, T. Holban, D. Jevtovic, K. Kase, B. Lakatos, I. Latysheva, R. Matulionyte, C. Oprea, A. Papadopoulos, N. Rukhadze, D....
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Free Medical Journals
od 1999 do Před 2 roky
Medline Complete (EBSCOhost)
od 1999-10-01 do Před 1 rokem
Wiley Free Content
od 1999 do Před 2 roky
PubMed
33021049
DOI
10.1111/hiv.12960
Knihovny.cz E-zdroje
- MeSH
- emtricitabin aplikace a dávkování MeSH
- HIV infekce prevence a kontrola MeSH
- látky proti HIV aplikace a dávkování MeSH
- lidé MeSH
- preexpoziční profylaxe metody statistika a číselné údaje MeSH
- tenofovir aplikace a dávkování MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa MeSH
OBJECTIVES: Pre-exposure prophylaxis (PrEP) for HIV infection is an important intervention for control of the HIV epidemic. The incidence of HIV infection is increasing in the countries of Central and Eastern Europe (CEE). Therefore, we investigated the change in PrEP use in CEE over time. METHODS: The Euroguidelines in Central and Eastern Europe (ECEE) Network Group was initiated in February 2016 to compare standards of care for HIV and viral hepatitis infections in CEE. Data on access to PrEP were collected from 23 countries through online surveys in May-June 2017 (76 respondents) and in November 2018-May 2019 (28 respondents). RESULTS: About 34.2% of respondents stated that tenofovir/emtricitabine (TDF/FTC) was licensed for use in their country in 2017, and 66.7% that it was licensed for use in 2018 (P = 0.02). PrEP was recommended in national guidelines in 39.5% of responses in 2017 and 40.7% in 2018 (P = 0.378). About 70.7% of respondents were aware of "informal" PrEP use in 2017, while 66.6% were aware of this in 2018 (P = 0.698). In 2018, there were 53 centres offering PreP (the highest numbers in Poland and Romania), whereas six countries had no centres offering PreP. The estimated number of HIV-negative people on PreP in the region was 4500 in 2018. Generic TDF/FTC costs (in Euros) ranged from €10 (Romania) to €256.92 (Slovakia), while brand TDF/FTC costs ranged from €60 (Albania) to €853 (Finland). CONCLUSIONS: Although the process of licensing TDF/FTC use for PrEP has improved, this is not yet reflected in the guidelines, nor has there been a reduction in the "informal" use of PrEP. PrEP remains a rarely used preventive method in CEE countries.
Belarusian State Medical University Minsk Belarus
Belgrade University School of Medicine Infectious Diseases Hospital Belgrade Serbia
Central Research Institute of Epidemiology Federal AIDS Centre Moscow Russian Federation
Clinic for Infectious Diseases Belgrade Serbia
Department of Adults' Infectious Diseases Medical University of Warsaw Warsaw Poland
Department of Infectious Diseases University Medical Center Ljubljana Ljubljana Slovenia
Department of Infectious Diseases West Tallinn Central Hospital Tallinn Estonia
Helsinki University Hospital Helsinki Finland
HIV Center University Hospital Pilsen Czech Republic
HIV Out Patient Clinic Hospital for Infectious Diseases Warsaw Poland
Infectious Diseases AIDS and Clinical Immunology Research Center Tbilisi Georgia
Lviv Regional Public Health Center Lviv Ukraine
National Center for Disease Control and Prevention Yerevan Armenia
National Centre of Infectious and Parasitic Diseases Sofia Bulgaria
Nicolae Testemițanu State University of Medicine and Pharmacy Chisinau Republic of Moldova
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22012564
- 003
- CZ-PrNML
- 005
- 20220506130354.0
- 007
- ta
- 008
- 220425s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/hiv.12960 $2 doi
- 035 __
- $a (PubMed)33021049
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Balayan, T $u National Center for Disease Control and Prevention, Yerevan, Armenia $1 https://orcid.org/0000000344784129
- 245 10
- $a Where are we with pre-exposure prophylaxis use in Central and Eastern Europe? Data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group / $c T. Balayan, J. Begovac, A. Skrzat-Klapaczyńska, I. Aho, I. Alexiev, P. Bukovinova, D. Salemovic, D. Gokengin, A. Harxhi, T. Holban, D. Jevtovic, K. Kase, B. Lakatos, I. Latysheva, R. Matulionyte, C. Oprea, A. Papadopoulos, N. Rukhadze, D. Sedlacek, J. Tomazic, A. Vassilenko, M. Vasylyev, A. Verhaz, N. Yancheva, O. Yurin, A. Horban, JD. Kowalska, ECEE Network Group
- 520 9_
- $a OBJECTIVES: Pre-exposure prophylaxis (PrEP) for HIV infection is an important intervention for control of the HIV epidemic. The incidence of HIV infection is increasing in the countries of Central and Eastern Europe (CEE). Therefore, we investigated the change in PrEP use in CEE over time. METHODS: The Euroguidelines in Central and Eastern Europe (ECEE) Network Group was initiated in February 2016 to compare standards of care for HIV and viral hepatitis infections in CEE. Data on access to PrEP were collected from 23 countries through online surveys in May-June 2017 (76 respondents) and in November 2018-May 2019 (28 respondents). RESULTS: About 34.2% of respondents stated that tenofovir/emtricitabine (TDF/FTC) was licensed for use in their country in 2017, and 66.7% that it was licensed for use in 2018 (P = 0.02). PrEP was recommended in national guidelines in 39.5% of responses in 2017 and 40.7% in 2018 (P = 0.378). About 70.7% of respondents were aware of "informal" PrEP use in 2017, while 66.6% were aware of this in 2018 (P = 0.698). In 2018, there were 53 centres offering PreP (the highest numbers in Poland and Romania), whereas six countries had no centres offering PreP. The estimated number of HIV-negative people on PreP in the region was 4500 in 2018. Generic TDF/FTC costs (in Euros) ranged from €10 (Romania) to €256.92 (Slovakia), while brand TDF/FTC costs ranged from €60 (Albania) to €853 (Finland). CONCLUSIONS: Although the process of licensing TDF/FTC use for PrEP has improved, this is not yet reflected in the guidelines, nor has there been a reduction in the "informal" use of PrEP. PrEP remains a rarely used preventive method in CEE countries.
- 650 _2
- $a látky proti HIV $x aplikace a dávkování $7 D019380
- 650 _2
- $a emtricitabin $x aplikace a dávkování $7 D000068679
- 650 _2
- $a HIV infekce $x prevence a kontrola $7 D015658
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a preexpoziční profylaxe $x metody $x statistika a číselné údaje $7 D065129
- 650 _2
- $a tenofovir $x aplikace a dávkování $7 D000068698
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Begovac, J $u School of Medicine, University of Zagreb, Zagreb, Croatia
- 700 1_
- $a Skrzat-Klapaczyńska, A $u Department of Adults' Infectious Diseases, Medical University of Warsaw, Warsaw, Poland
- 700 1_
- $a Aho, I $u Helsinki University Hospital, Helsinki, Finland
- 700 1_
- $a Alexiev, I $u National Centre of Infectious and Parasitic Diseases, Sofia, Bulgaria
- 700 1_
- $a Bukovinova, P $u Deptartment of Infectious Diseases and Geographical Medicine UH, University Hospital, Bratislava, Slovakia
- 700 1_
- $a Salemovic, D $u Clinic for Infectious Diseases, Belgrade, Serbia
- 700 1_
- $a Gokengin, D $u Ege University, Izmir, Turkey
- 700 1_
- $a Harxhi, A $u Department of Infectious Disease, Faculty of Medicine, University Hospital Center of Tirana, Tirana, Albania
- 700 1_
- $a Holban, T $u Nicolae Testemițanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova
- 700 1_
- $a Jevtovic, D $u Belgrade University School of Medicine Infectious Diseases Hospital, Belgrade, Serbia
- 700 1_
- $a Kase, K $u Department of Infectious Diseases, West Tallinn Central Hospital, Tallinn, Estonia
- 700 1_
- $a Lakatos, B $u Saint Laszlo Hospital National Center of HIV, Semmelweis University Faculty of Infectious Diseases, Budapest, Hungary
- 700 1_
- $a Latysheva, I $u Republican Clinical Hospital of Infectious Diseases of Ministry of Healthcare of Russian Federation, St Petersburg, Russia
- 700 1_
- $a Matulionyte, R $u Department of Infectious Diseases and Dermatovenerology, Infectious Diseases Centre, Vilnius University, Vilnius, Lithuania
- 700 1_
- $a Oprea, C $u Victor Babes Clinical Hospital for Infectious Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania $1 https://orcid.org/0000000195812527
- 700 1_
- $a Papadopoulos, A $u Medical School -National and Kapodistrian University of Athens, University General Hospital "ATTIKON", Athens, Greece
- 700 1_
- $a Rukhadze, N $u Infectious Diseases, AIDS & Clinical Immunology Research Center, Tbilisi, Georgia
- 700 1_
- $a Sedlacek, D $u HIV Center University Hospital, Pilsen, Czech Republic
- 700 1_
- $a Tomazic, J $u Department of Infectious Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Vassilenko, A $u Belarusian State Medical University, Minsk, Belarus
- 700 1_
- $a Vasylyev, M $u Lviv Regional Public Health Center, Lviv, Ukraine
- 700 1_
- $a Verhaz, A $u Clinic for Infectious Diseases, University Clinical Center of the Republic of Srpska, Banja Luka, Banja Luka, RS, Bosnia & Herzegovina, Banja Luka, Bosnia and Herzegovina
- 700 1_
- $a Yancheva, N $u Department for AIDS, Specialized Hospital for Active Treatment of Infectious and Parasitic Diseases - Sofia, Medical University Sofia, Sofia, Bulgaria
- 700 1_
- $a Yurin, O $u Central Research Institute of Epidemiology, Federal AIDS Centre, Moscow, Russian Federation
- 700 1_
- $a Horban, A $u Department of Adults' Infectious Diseases, Medical University of Warsaw, Warsaw, Poland
- 700 1_
- $a Kowalska, J D $u Department of Adults' Infectious Diseases, Medical University of Warsaw, Warsaw, Poland $u HIV Out-Patient Clinic, Hospital for Infectious Diseases, Warsaw, Poland $1 https://orcid.org/0000000311664462
- 710 2_
- $a ECEE Network Group
- 773 0_
- $w MED00007240 $t HIV medicine $x 1468-1293 $g Roč. 22, č. 1 (2021), s. 67-72
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33021049 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130346 $b ABA008
- 999 __
- $a ok $b bmc $g 1789962 $s 1163765
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 22 $c 1 $d 67-72 $e 20201005 $i 1468-1293 $m HIV medicine $n HIV Med $x MED00007240
- LZP __
- $a Pubmed-20220425
